Sign in Register

Drug class

Anticonvulsant - Functionalized Amino Acid

The drug class descriptor "Anticonvulsant - Functionalized Amino Acid" designates a chemical and therapeutic subclass of antiepileptic agents structurally derived from D-serine, prototyped by lacosamide. Read more about Anticonvulsant - Functionalized Amino Acid

49 drugs in this class 46 manufacturers

Advertisement

Related classes & indications

Antipsychotics, AtypicalCNS, pain & psychiatry · 296 prescription drugs Antidepressant Serotonin-Norepinephrine Reuptake Inh.(SNRIs)CNS, pain & psychiatry · 127 prescription drugs Focal EpilepsyTop indication · 177 prescription drugs

Drugs in Anticonvulsant - Functionalized Amino Acid

Showing 37–45 of 49 drugs

LACOSAMIDE

ANTICONVULSANTS · FOCAL EPILEPSY ·+2
NOVITIUM/ANI PH

LACOSAMIDE

ANTICONVULSANTS · FOCAL EPILEPSY ·+2
FRESENIUS KABI

LACOSAMIDE

ANTICONVULSANTS · FOCAL EPILEPSY ·+2
TRIGEN LABORATO

LACOSAMIDE

ANTICONVULSANTS · FOCAL EPILEPSY ·+2
UNICHEM PHARMAC

LACOSAMIDE

ANTICONVULSANTS · FOCAL EPILEPSY ·+2
PRECISION DOSE

LACOSAMIDE

ANTICONVULSANTS · FOCAL EPILEPSY ·+2
GSK Consumer Healthcare

LACOSAMIDE

ANTICONVULSANTS · FOCAL EPILEPSY ·+2
AJENAT PHARMACE

LACOSAMIDE

ANTICONVULSANTS · FOCAL EPILEPSY ·+2
KESIN PHARMA

LACOSAMIDE

ANTICONVULSANTS · FOCAL EPILEPSY ·+2
BRYANT RANCH PR
Filter & compare in the drug finder → Opens the drug finder with Anticonvulsant - Functionalized Amino Acid preselected. Add indication or manufacturer filters there.

About Anticonvulsant - Functionalized Amino Acid.

The drug class descriptor "Anticonvulsant - Functionalized Amino Acid" designates a chemical and therapeutic subclass of antiepileptic agents structurally derived from D-serine, prototyped by lacosamide.

Agents in this class exert their primary therapeutic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels, thereby stabilizing hyperexcitable neuronal membranes and curbing repetitive, high-frequency neuronal firing without disrupting physiological fast inactivation.

Clinically, these agents are indicated for the management of epilepsy, specifically as monotherapy or adjunctive therapy for partial-onset seizures and primary generalized tonic-clonic seizures.